Halozyme Reports Fourth Quarter And Full Year 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Halozyme Therapeutics (HALO) Tops Q4 EPS by 7c
February 28, 2017 4:23 PM ESTHalozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of ($0.21), $0.07 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $39 million versus the consensus estimate of $38.37 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
... More